RedHill Biopharma Ltd – (RDHL) Reaches New 52-Week High at $16.54
Shares of RedHill Biopharma Ltd – (NASDAQ:RDHL) hit a new 52-week high on Thursday . The company traded as high as $16.54 and last traded at $16.20, with a volume of 113,514 shares traded. The stock had previously closed at $15.31.
A number of analysts have recently weighed in on RDHL shares. Zacks Investment Research raised shares of RedHill Biopharma Ltd – from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Tuesday, June 28th. FBR & Co reaffirmed a “buy” rating on shares of RedHill Biopharma Ltd – in a research note on Tuesday, May 3rd. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $26.00.
The stock’s market cap is $204.63 million. The stock’s 50 day moving average price is $11.90 and its 200-day moving average price is $11.26.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last announced its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.52. Equities research analysts forecast that RedHill Biopharma Ltd – will post ($2.06) EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.